<DOC>
	<DOCNO>NCT00075634</DOCNO>
	<brief_summary>This phase I trial study side effect best dose decitabine give together doxorubicin cyclophosphamide treat child relapse refractory solid tumor neuroblastoma . Drugs use chemotherapy , decitabine , doxorubicin , cyclophosphamide , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Decitabine , Doxorubicin , Cyclophosphamide Treating Children With Relapsed Refractory Solid Tumors Neuroblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose decitabine combination doxorubicin cyclophosphamide child relapse refractory solid tumor neuroblastoma . II . Determine toxic effect regimen patient . III . Determine whether decitabine induces tumor caspase-8 demethylation expression patient . SECONDARY OBJECTIVES : I . Determine pharmacokinetics low-dose decitabine patient . II . Determine biological clinical response patient treat regimen . III . Compare pattern peripheral blood gene expression , use gene expression profiling , patient treatment decitabine . OUTLINE : This multicenter , dose-escalation study decitabine . PART A ( solid tumor patient ) : Patients receive decitabine IV 1 hour day 0-6 doxorubicin IV 15 minute cyclophosphamide IV 1 hour day 7 . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 8 continue blood count recover OR pegfilgrastim SC day 8 9* . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos decitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . NOTE : *For patient &gt; 45 kg PART B ( neuroblastoma patient ) : Once MTD determine part A , patient treat part A MTD . Patients follow 30 day .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically confirm diagnosis either following : Solid tumor ( part A ) No lymphoma Neuroblastoma ( part B ) Original diagnosis may base elevated urine vanillylmandelic acid ( VMA ) homovanillic acid ( HVA ) bone marrow examination Accessible disease bone marrow aspirate tumor biopsy No laparotomy , thoracotomy , endoscopy , craniotomy biopsy No known curative therapy OR therapy proven prolong survival acceptable quality life available No known brain spinal cord metastases No CNS tumor Performance status Karnofsky 50100 % ( patient 11 21 year age ) Performance status Lansky 50100 % ( patient ≤ 10 year age ) Parts A B without bone marrow infiltration : Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion independent ) Part B bone marrow infiltration ( i.e. , tumor metastatic bone marrow granulocytopenia , anemia , and/or thrombocytopenia ) : Absolute neutrophil count ≥ 750/mm^3 Platelet count ≥ 50,000/mm^3 ( transfusion independent ) Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) No sickle cell anemia Bilirubin ≤ 1.5 mg/dL ALT ≤ 5 time upper limit normal No significant hepatic dysfunction would compromise tolerability decitabine interfere study procedure result Creatinine base age follow : ≤ 0.8 mg/dL ( 5 year age ) ≤ 1.0 mg/dL ( 6 10 year age ) ≤ 1.2 mg/dL ( 11 15 year age ) ≤ 1.5 mg/dL ( 16 21 year age ) Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min No significant renal dysfunction would compromise tolerability decitabine interfere study procedure result Shortening fraction ≥ 28 % echocardiogram Ejection fraction ≥ 45 % MUGA No significant pulmonary dysfunction would compromise tolerability decitabine interfere study procedure result Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction attribute compound similar chemical biological composition agent use study No uncontrolled serious infection No significant endorgan dysfunction would compromise tolerability decitabine interfere study procedure result Recovered prior immunotherapy At least 7 day since prior biologic therapy More 1 week since prior growth factor therapy ( 2 week pegfilgrastim ) More 2 week since prior epoetin alfa At least 6 month since prior autologous stem cell transplantation At least 6 month since prior allogeneic bone marrow transplantation Patients must full organ recovery evidence graftversushost disease No concurrent immunomodulating agent No concurrent immunotherapy No concurrent biologic therapy No concurrent epoetin alfa Recovered prior chemotherapy More 2 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) Prior total lifetime cumulative anthracycline dose ≤ 450 mg/m^2 doxorubicin equivalent No concurrent chemotherapy No concurrent hydroxyurea Recovered prior radiotherapy More 2 week since prior local palliative small port radiotherapy More 6 month since prior substantial bone marrow irradiation ( e.g. , craniospinal irradiation , total body irradiation , hemipelvic irradiation ) No concurrent radiotherapy No concurrent anticancer therapy No concurrent investigational agent Concurrent oral iron supplementation patient know iron deficiency microcytic hypochromic anemia allow</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>